NICE guidance (NG28) recommends GLP-1 receptor agonists for type 2 diabetes in specific clinical circumstances, typically when metformin and other treatments have not achieved glycaemic targets
An orally active allosteric GLP-1 receptor agonist is neuroprotective in cellular and rodent models of stroke
Rare but serious adverse effects, including pancreatitis, gallbladder disease, or severe gastrointestinal adverse events, may require stopping treatment
Microdosing a GLP-1 (aka Ozempic, Wegovy, semaglutide, tirzepatide, zepbound, etc) is taking a lower than the lowest granular dose prescribed by the FDA for weight loss, but some people use it interchangeably when referring to one of the smaller doses on the dosing schedule
Individual results and eligibility vary based on clinical evaluation and lab results
A cool room facilitates this natural process